Previous 10 | Next 10 |
Dosing is underway in a Phase 2 registrational trial in China evaluating I-Mab Biopharma's TJ202/MOR202, a fully human monoclonal antibody targeting a protein found on the surface of cancer cells called CD38, in patients with relapsed/refractory multiple myeloma (MM). The company in-lice...
Q4 2019 has been the best quarter ([[IBB]] up 22.5% [[XBI]] up 26.7%) for biotech investors since Q1 2015, which was the top of 2014-2015 rally. This 20+% rally is largely attributed to Fed's overall easing stance, increased mergers & acquisitions, positive regulatory backdrop, solid trial...
bluebird bio, Inc. (NASDAQ: BLUE) today announced that members of the management team will present at the following upcoming investor conferences in January: Goldman Sachs 12 th Annual Healthcare CEOs Unscripted: A View from the Top, Thursday, January 9, at 2:00 p.m. ET at the Goldman ...
The annual American Society of Hematology (ASH) conference has historically been fertile ground for revolutionary advances in the treatment of blood disorders and cancers. This year was no exception. Among the thousands of presentations at the conference, a number of groundbreaking advances were...
Johnson & Johnson ( JNJ ) announced that it had achieved positive preliminary data from a phase 1 study , using one of its CAR-T therapies JNJ-4528 to treat patients with advanced multiple myeloma. Tumors had shrunk in all patients for the study, and with that positive outcome the com...
2020 should be another favorable year for healthcare investing, though the gains thus far in 2019 should necessitate greater selectivity. The overriding investment theme in healthcare, in my opinion, is the fact that the dual tailwinds of the aging of the population and the obesity epidemic (b...
Introduction Based on Kirkland Lake Gold’s ( KL ) share price change since the merger announcement, it appears the market thinks its equal to 1.5! This analysis attempts to answer this question with an analysis of key operating and financial data one-year forward. It focuses on th...
bluebird bio (BLUE) and its partner Bristol-Myers Squibb (BMY) announced positive results from several studies using its LentiGlobin gene therapy to treat patients with beta-thalassemia. The more prominent news item involves long-term data from one study, which showed that those treated ...
Arrowhead Pharmaceuticals (NASDAQ: ARWR ) initiated with Market Perform rating at Oppenheimer. More news on: Arrowhead Pharmaceuticals, Inc., Exact Sciences Corporation, Ionis Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
Sangamo Therapeutics ( SGMO -1% ) is down again, albeit modestly on average volume. Shares have sold off over 30% since touching $12.33 on Monday. More news on: Sangamo Therapeutics, Inc., bluebird bio, Inc., Healthcare stocks news, Stocks on the move, Read more ...
News, Short Squeeze, Breakout and More Instantly...
The downtrodden biotech space has kicked off the second half of 2022 with a boom. Hard-hit gene-editing and gene therapy companies in particular have started the back half of the year on the right foot. Underscoring this point, Bluebird Bio (NASDAQ: BLUE) stock has already risen by ...
Bluebird Bio 's (NASDAQ: BLUE) stock motored upward above 24% amid an unusually high volume of trading before pulling back to around 13.3% by noon on Tuesday, likely as a result of a short squeeze . More than 34.6% of its floating shares were held short as of June 15, which puts...